Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors

Michael B. Plewe, Nadezda V. Sokolova, Vidyasagar Reddy Gantla, Eric R. Brown, Shibani Naik, Alexandra Fetsko, Donald D. Lorimer, Donald D. Lorimer, David M. Dranow, David M. Dranow, Hayden Smutney, Hayden Smutney, Jameson Bullen, Jameson Bullen, Rana Sidhu, Rana Sidhu, Arshil Master, Arshil Master, Junru Wang, Junru WangE. Adam Kallel, Lihong Zhang, Birte Kalveram, Alexander N. Freiberg, Greg Henkel, Ken McCormack

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


We identified and explored the structure-activity-relationship (SAR) of an adamantane carboxamide chemical series of Ebola virus (EBOV) inhibitors. Selected analogs exhibited half-maximal inhibitory concentrations (EC50 values) of ∼10-15 nM in vesicular stomatitis virus (VSV) pseudotyped EBOV (pEBOV) infectivity assays, low hundred nanomolar EC50 activity against wild type EBOV, aqueous solubility >20 mg/mL, and attractive metabolic stability in human and nonhuman liver microsomes. X-ray cocrystallographic characterizations of a lead compound with the EBOV glycoprotein (GP) established the EBOV GP as a target for direct compound inhibitory activity and further provided relevant structural models that may assist in identifying optimized therapeutic candidates.

Original languageEnglish (US)
Pages (from-to)1160-1167
Number of pages8
JournalACS Medicinal Chemistry Letters
Issue number6
StatePublished - Jun 11 2020


  • Ebola virus
  • adamantane carboxamide
  • cell entry
  • glycoprotein

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors'. Together they form a unique fingerprint.

Cite this